Manage Your Liver
Q:

Prevent liver cell damage: A new era of liver disease treatment

Prevent liver cell damage: A new era of liver disease treatment
A:

There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.

 

The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Therefore, pharmaceutical companies have recently shifted their focus onto the development of cure for fatty liver and NASH.

 

As the cause of NASH is still unknown, to date, there are no available treatment options. Unlike hepatitis C, where the liver damage is caused by hepatitis viruses; the only thing we know about NASH is that the accumulated fat is related to liver injury, but the mechanism is unknown. . In this case, anti-viral medication will not be effective for NASH patients.

 

New drug in development focuses on preventing liver cell damage

New drugs for NASH are in development,  they are designed to block the progression of liver cell damage, prevent chronic liver inflammation and cirrhosis, and ultimately help to improve liver function for NASH patients.

 

Pharmaceutical companies are hoping that this new drug can minimize liver injury and help NASH patients to reduce risk of developing chronic liver diseases. The drug is currently under clinical trial; enrolment of a final-stage trial of 2,000 people is expected to be completed next year, with interim results due in 2019. Early results show that the new drug can lower patients’ ALT level, which is a good indication that liver injury is reduced. [2] 

 

New drugs may improve but not normalize liver function

The use of chemicals and drugs in treating liver diseases has its downsides. Patients are required to use the inhibitor in the long term in order to prevent liver injury this means that they will be consuming chemicals and toxins on a daily basis. Regardless of the intensity of side effects, long term use of any medication will no doubt negatively affect our health.

 

This might be the reason why the new drugs in development are unable to normalize ALT and liver function, even though liver damage may be reduced. These drugs themselves contain toxic substances which are harmful to our bodies in some way.

 

If you want to know more about the upcoming new drugs and how YHK can help to stop NASH, please contact our support team!

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Since the introduction of direct-acting antiviral (DAA) therapy, treatment for hepatitis C (HCV) was revolutionized, as patient outcomes are improved with fewer side effects and high cure rate. However, there is significant debate in the society based on studies that suggest HCV cure does not eliminate risk for hepatocellular carcinoma (HCC) or liver cancer. Other research suggests the possibility of increased risk of developing liver cancer during and after DAA treatment in patients with hep
A:
Chronic hepatitis C is a slow and progressive disease that causes liver inflammation, fibrosis and cirrhosis. Over a long period of time, hepatitis virus can cause long term damage that is often thought to be irreversible. But recent research is suggesting otherwise, that fibrotic or cirrhotic liver is reversible, allowing patients to regain liver function and improve health. The danger of cirrhosis Cirrhosis is end stage liver fibrosis, it is a
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C viruses share a common characteristic to other chronic liver diseases; it could damage the patients’ liver cells. Hepatitis C patients should focus on stopping or reducing the damage in the liver, and this focus should be the same for other chronic liver diseases e.g. hepatitis B, fatty liver disease, NASH etc. And this is exactly what YHK can do.   YHK can stop liver cells damage caused by hepatitis viruses, and can repair damaged liver cells, to he
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us